Role of 5 alpha-reductase inhibitors in the management of prostate cancer

References

• AhmedSLindseyBDaviesJ2005Emerging minimally invasive techniques for treating localized prostate cancerBJU International961230416287436
   PubMed Web of Science ®Google Scholar
• AndrioleGBostwickDBrawleyO2004Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trialJ Urol17213141715371831
   PubMed Web of Science ®Google Scholar
• AndrioleGLieberMSmithJ1995Treatment with finasteride following radical prostatectomy for prostate cancerUrology4549177533461
   PubMed Web of Science ®Google Scholar
• AndrioleGLGuessHAEpsteinJI1998Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety StudyUrology52195201discussion 201–2.9697781
   PubMed Web of Science ®Google Scholar
• AndrioleGLHumphreyPRayP2004Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancerJ Urol1729151915310997
   PubMed Web of Science ®Google Scholar
• BarqawiABMoulJWZiadaA2003Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapyUrology62872614624911
   PubMed Web of Science ®Google Scholar
• BramsonHNHermannDBatchelorKW1997Unique preclinical characteristics of GG745, a potent dual inhibitor of 5ARJ Pharmacol Exper Ther28214965029316864
   PubMed Web of Science ®Google Scholar
• BrooksJRBaptistaEMBermanC1981Response of rat ventral prostate to a new and novel 5 alpha-reductase inhibitorEndocrinology10983067262023
   PubMed Web of Science ®Google Scholar
• BrooksJRBermanDGlitzerMS1982Effect of a new 5 alpha-reductase inhibitor on size, histologic characteristics, and androgen concentrations of the canine prostateProstate335447079196
   PubMed Web of Science ®Google Scholar
• BrufskyAFontaine-RothePBerlaneK1997Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostateUrology49913209187700
   PubMed Web of Science ®Google Scholar
• CarterHBWalshPCLandisP2002Expectant management of nonpalpable prostate cancer with curative intent: preliminary resultsJ Urol1671231411832703
   PubMed Web of Science ®Google Scholar
• CooksonM2006Guidelines for Prostate Cancer. American Urological Association Annual Meeting, Atlanta, GA. Webcast [online]. Accessed 10 October 2006. URL: http://webcasts.prous.com/aua2006/article.asp?AID=39&CID=YY&CLID=2
   Google Scholar
• EtzioniRDHowladerNShawPA2005Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trialJ Urol17487781Erratum: J Urol, 174:2071.16093979
   PubMed Web of Science ®Google Scholar
• FleshnerNETrachtenbergJ1992Sequential androgen blockade: a biological study in the inhibition of prostatic growthJ Urol1481928311331549
   PubMed Web of Science ®Google Scholar
• GormleyGJStonerEBruskewitzRC1992The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study GroupN Engl J Med3271185911383816
   PubMed Web of Science ®Google Scholar
• GroverSLowensteynIHajekD2006Do the benefits of finasteride outweigh the risks in the prostate cancer prevention trial?J Urol1759348discussion 938.16469585
   PubMed Web of Science ®Google Scholar
• IehleCRadvanyiFGil Diez de MedinaS1999Differences in steroid 5alpha-reductase iso-enzymes expression between normal and pathological human prostate tissueJ Steroid Biochem Mol Biol681899510416833
   PubMed Web of Science ®Google Scholar
• Imperato-McGinleyJGautierTZirinskyK1992Prostate visualization studies in males homozygous and heterozygous for 5 alpha-reductase deficiencyJ Clin Endocrinol Metab75102261400866
   PubMed Web of Science ®Google Scholar
• Imperato-McGinleyJGuerreroLGautierT1974Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditismScience1861213154432067
   PubMed Web of Science ®Google Scholar
• IversenPTyrrellCJKaisaryAV2000Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followupJ Urol16415798211025708
   PubMed Web of Science ®Google Scholar
• JemalASiegelRWardE2006Cancer statistics, 2006CA Cancer J Clin561063016514137
   PubMed Web of Science ®Google Scholar
• McConnellJDBruskewitzRWalshP1998The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study GroupN Engl J Med338557639475762
   PubMed Web of Science ®Google Scholar
• McConnellJDRoehrbornCGBautistaOM2003The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasiaN Engl J Med34923879814681504
   PubMed Web of Science ®Google Scholar
• McLeodDGSeeWAKlimbergI2006The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7-year median followupJ Urol176758016753373
   PubMed Web of Science ®Google Scholar
• OhWKManolaJBittmannL2003Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-upUrology629910412837431
   PubMed Web of Science ®Google Scholar
• PartinAWRodriguezR2002The molecular biology, endocrinology, and physiology of the prostate and seminal vesiclesWalshPCRetikAVaughanECampbell’s Urology8th edPhiladelphiaSaunders123796
   Google Scholar
• PotoskyALKnopfKCleggLX2001Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes StudyJ Clin Oncol193750711533098
   PubMed Web of Science ®Google Scholar
• PrestiJCJrFairWRAndrioleG1992Multicenter, randomized, double-blind, placebo controlled study to investigate the effect of finasteride (MK-906) on stage D prostate cancerJ Urol148120141383574
   PubMed Web of Science ®Google Scholar
• RiesLHarkinsDKrapchoM2006SEER Cancer Statistics Review, 1975–2003. National Cancer Institute [online]. Accessed 2 October 2006. URL: http://seer.cancer.gov/csr/1975_2003/
   Google Scholar
• RittmasterRSStonerEThompsonDL1989Effect of MK-906, a specific 5 alpha-reductase inhibitor, on serum androgens and androgen conjugates in normal menJ Androl10259622550402
   PubMed Web of Science ®Google Scholar
• RoehrbornCGBoylePNickelJC2002Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasiaUrology604344112350480
   PubMed Web of Science ®Google Scholar
• ScardinoPT2003The prevention of prostate cancer—the dilemma continuesN Engl J Med349297912824458
   PubMed Web of Science ®Google Scholar
• ScholzMCJennrichRIStrumSB2006Intermittent use of testosterone inactivating pharmaceuticals using finasteride prolongs the time off periodJ Urol1751673816600727
   PubMed Web of Science ®Google Scholar
• SpryNAKristjansonLHootonB2006Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancerEur J Cancer4210839216632343
   PubMed Web of Science ®Google Scholar
• SteinerJF1996Clinical pharmacokinetics and pharmacodynamics of finasterideClin Pharmacokinetics301627
   PubMed Web of Science ®Google Scholar
• StonerE1990The clinical development of a 5-alpha-reductase inhibitor, finasterideJ Steroid Biochem Mol Biol3737581701660
   PubMed Web of Science ®Google Scholar
• StonerE1992The clinical effects of a 5 alpha-reductase inhibitor, finasteride, on benign prostatic hyperplasia. The Finasteride Study GroupJ Urol14712983021373779
   PubMed Web of Science ®Google Scholar
• TayMHKaufmanDSReganMM2004Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostateAnn Oncol15974815151957
   PubMed Web of Science ®Google Scholar
• ThompsonIMAnkerstDPChiC2005Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lowerJAMA294667015998892
   PubMed Web of Science ®Google Scholar
• ThompsonIMChiCAnkerstDP2006Effect of finasteride on the sensitivity of PSA for detecting prostate cancerJ Natl Cancer Inst9811283316912265
   PubMed Web of Science ®Google Scholar
• ThompsonIMGoodmanPJTangenCM2003The influence of finasteride on the development of prostate cancerN Engl J Med3492152412824459
   PubMed Web of Science ®Google Scholar
• TooherRSwindlePWooH2006Laparoscopic radical prostatectomy for localized prostate cancer: a systematic review of comparative studiesJ Urol17520111716697787
   PubMed Web of Science ®Google Scholar
• TsukamotoSAkazaHOnozawaM1998A five-alpha reductase inhibitor or an antiandrogen prevents the progression of microscopic prostate carcinoma to macroscopic carcinoma in ratsCancer8253179452271
   PubMed Web of Science ®Google Scholar
• TyrrellCJKaisaryAVIversenP1998A randomised comparison of ‘Casodex’ (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancerEur Urol33447569643663
   PubMed Web of Science ®Google Scholar
• WalshPCMaddenJDHarrodMJ1974Familial incomplete male pseudohermaphroditism, type 2. Decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadiasN Engl J Med29194494413434
   PubMed Web of Science ®Google Scholar
• WangLGMencherSKMcCarronJP2004The biological basis for the use of an anti-androgen and a 5-alpha-reductase inhibitor in the treatment of recurrent prostate cancer: Case report and reviewOncol Rep111325915138573
   PubMed Web of Science ®Google Scholar
• WenderothUKGeorgeFWWilsonJD1983The effect of a 5 alpha-reductase inhibitor on androgen-mediated growth of the dog prostateEndocrinology113569736872940
   PubMed Web of Science ®Google Scholar
• ZaccheoTGiudiciDdi SalleE1997Effect of turosteride, a 5 alpha-reductase inhibitor, on the Dunning R3327 rat prostatic carcinomaProstate3085919051146
   PubMed Web of Science ®Google Scholar
• ZaccheoTGiudiciDdi SalleE1998Effect of early treatment of prostate cancer with the 5alpha-reductase inhibitor turosteride in Dunning R3327 prostatic carcinoma in ratsProstate35237429609545
   PubMed Web of Science ®Google Scholar